Wilkinson GR - Search Results

1

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.

Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, Shen DD, Watkins PB, Wilkinson GR, Kharasch ED, Thummel KE. Lin YS, et al. Among authors: wilkinson gr. Pharmacogenetics. 2001 Dec;11(9):781-91. doi: 10.1097/00008571-200112000-00006. Pharmacogenetics. 2001. PMID: 11740342

2

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. Thummel KE, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 1996 May;59(5):491-502. doi: 10.1016/S0009-9236(96)90177-0. Clin Pharmacol Ther. 1996. PMID: 8646820 Clinical Trial.

3

In vitro and in vivo drug interactions involving human CYP3A.

Thummel KE, Wilkinson GR. Thummel KE, et al. Among authors: wilkinson gr. Annu Rev Pharmacol Toxicol. 1998;38:389-430. doi: 10.1146/annurev.pharmtox.38.1.389. Annu Rev Pharmacol Toxicol. 1998. PMID: 9597161 Review.

4

CYP3A activity in European American and Japanese men using midazolam as an in vivo probe.

Tateishi T, Watanabe M, Nakura H, Asoh M, Shirai H, Mizorogi Y, Kobayashi S, Thummel KE, Wilkinson GR. Tateishi T, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 2001 May;69(5):333-9. doi: 10.1067/mcp.2001.115447. Clin Pharmacol Ther. 2001. PMID: 11372001 Clinical Trial.

5

Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.

Kinirons MT, O'Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ, Wilkinson GR. Kinirons MT, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 1999 Sep;66(3):224-31. doi: 10.1016/S0009-9236(99)70029-9. Clin Pharmacol Ther. 1999. PMID: 10511057 Clinical Trial.

6

Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.

Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, Wilkinson GR. Floyd MD, et al. Among authors: wilkinson gr. Pharmacogenetics. 2003 Oct;13(10):595-606. doi: 10.1097/00008571-200310000-00003. Pharmacogenetics. 2003. PMID: 14515058

7

Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects.

Adedoyin A, Prakash C, O'Shea D, Blair IA, Wilkinson GR. Adedoyin A, et al. Among authors: wilkinson gr. Pharmacogenetics. 1994 Feb;4(1):27-38. Pharmacogenetics. 1994. PMID: 8004130

8

Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.

Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Xie HG, et al. Among authors: wilkinson gr. Pharmacogenetics. 1999 Oct;9(5):539-49. Pharmacogenetics. 1999. PMID: 10591534

9

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.

Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI. Dickmann LJ, et al. Among authors: wilkinson gr. Mol Pharmacol. 2001 Aug;60(2):382-7. doi: 10.1124/mol.60.2.382. Mol Pharmacol. 2001. PMID: 11455026

10

Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.

Kim JS, Nafziger AN, Tsunoda SM, Choo EE, Streetman DS, Kashuba AD, Kulawy RW, Beck DJ, Rocci ML Jr, Wilkinson GR, Greenblatt DJ, Bertino JS Jr. Kim JS, et al. Among authors: wilkinson gr. J Clin Pharmacol. 2002 Apr;42(4):376-82. J Clin Pharmacol. 2002. PMID: 11936561

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

239 results

Search Page

Filters